Tenax Therapeutics, Inc. TENX
Set alert
1.79 USD -0.07 -3.76%
At close · Oct 30
1.79 0.00 0.00%
After hours · Oct 30, 7:59 PM ET
1.73 Day range 1.85
1.36 52-week range 18.32
- YTD
- -85.32%
- 1 year
- -76.04%
- Open
- 1.83
- Prev close
- 1.86
- Mkt cap
- 66.99M
- Vol
- 888.06K
- Avg vol
- 5.69M
- EPS
- -1.48
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.73
- High
- 1.85
- Forward P/E
- -1.06
- Beta
- 2.15
- Short ratio
- 1.46
- Inst. own
- 47.95%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Apr 1, 2024
- 50-d avg
- 4.96
- 200-d avg
- 3.94
- 1y target
- 16.30
2Y chart
Events in this range
- Nov 13, 2024Earnings: -0.19; estimate -1.38; surprise 86.23%
Signals (79)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 1 day ago |
| SMA: Bullish | Oct 28, 2026 | 3 days ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| MACD: Buy Signal | Aug 27, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| RSI: Oversold | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Aug 5, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 16, 2026 | 3 months ago |
| RSI: Overbought | Jul 6, 2026 | 3 months ago |
| RSI: Overbought | Jun 30, 2026 | 4 months ago |
| SMA: Bullish | Jun 23, 2026 | 4 months ago |
| SMA: Bullish | Jun 12, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 12, 2026 | 4 months ago |
| SMA: Bearish | Jun 5, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 3, 2026 | 5 months ago |
| MACD: Buy Signal | May 21, 2026 | 5 months ago |
| SMA: Bearish | Apr 29, 2026 | 6 months ago |
| SMA: Bullish | Apr 17, 2026 | 6 months ago |
| SMA: Bearish | Apr 16, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 7, 2026 | 6 months ago |
| SMA: Bullish | Mar 25, 2026 | 7 months ago |
| SMA: Bearish | Mar 24, 2026 | 7 months ago |
| SMA: Bullish | Mar 10, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 10, 2026 | 7 months ago |
| SMA: Bearish | Feb 13, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 23, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 12, 2026 | 9 months ago |
| RSI: Overbought | Jan 12, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 31, 2025 | 10 months ago |
| RSI: Overbought | Dec 24, 2025 | 10 months ago |
| RSI: Overbought | Dec 12, 2025 | 10 months ago |
| RSI: Overbought | Dec 4, 2025 | 11 months ago |
| RSI: Overbought | Nov 24, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 18, 2025 | 11 months ago |
| SMA: Bullish | Nov 14, 2025 | 11 months ago |
| SMA: Bearish | Nov 13, 2025 | 11 months ago |
| MACD: Sell Signal | Oct 14, 2025 | 1 year ago |
| RSI: Overbought | Sep 18, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 4, 2025 | 1 year ago |
| SMA: Bullish | Aug 29, 2025 | 1 year ago |
| SMA: Bullish | Aug 29, 2025 | 1 year ago |
| SMA: Bearish | Aug 25, 2025 | 1 year ago |
| SMA: Bearish | Aug 25, 2025 | 1 year ago |
| SMA: Bullish | Aug 14, 2025 | 1 year ago |
| SMA: Bearish | Aug 8, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 7, 2025 | 1 year ago |
| SMA: Bullish | Jul 14, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 14, 2025 | 1 year ago |
| SMA: Bearish | Jun 30, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 30, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 26, 2025 | 1 year ago |
| SMA: Bullish | Jun 25, 2025 | 1 year ago |
| SMA: Bearish | Jun 23, 2025 | 1 year ago |
| SMA: Bullish | Jun 20, 2025 | 1 year ago |
| SMA: Bearish | Jun 17, 2025 | 1 year ago |
| SMA: Bullish | Jun 16, 2025 | 1 year ago |
| SMA: Bearish | Jun 13, 2025 | 1 year ago |
| SMA: Bullish | Jun 12, 2025 | 1 year ago |
| SMA: Bearish | Jun 10, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 4, 2025 | 1 year ago |
| SMA: Bullish | May 16, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 24, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 3, 2025 | 1 year ago |
| SMA: Bearish | Apr 1, 2025 | 1 year ago |
| SMA: Bullish | Mar 28, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 28, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 27, 2025 | 1 year ago |
| SMA: Bearish | Mar 24, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 13, 2025 | 1 year ago |
| SMA: Bearish | Feb 24, 2025 | 1 year ago |
| SMA: Bullish | Feb 21, 2025 | 1 year ago |
| SMA: Bearish | Feb 20, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 19, 2025 | 1 year ago |
| RSI: Overbought | Feb 7, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 6, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 10, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 30, 2024 | 1 year ago |
| RSI: Overbought | Dec 30, 2024 | 1 year ago |
| RSI: Overbought | Nov 25, 2024 | 1 year ago |
Key statistics
- Market cap
- 18.71M
- Enterprise value
- 7.73M
- Trailing P/E
- 0.00
- Forward P/E
- -1.06
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.20
- EPS (TTM)
- -13.05
- Beta
- 2.15
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -7.55M
- Total cash
- 9.38M
- Total debt
- 278.80K
- Return on equity
- -113.79%
- Shares outstanding
- 3.41M
- Short % of float
- 4.10%
- 50-day average
- 4.96
- 200-day average
- 3.94
Analyst view
Consensus: none
Price target (mean) 16.30 +810.6% upside
Now 1.79
- Target (low)
- 7.00
- Target (mean)
- 16.30
- Target (high)
- 30.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Apr 1, 2024
Expected Apr 1, 2024. Consensus EPS estimate -0.4225.
Financials — quick view
TENX Revenue — quarterly 0
TENX Net income — quarterly -17.80M
TENX EPS — quarterly -0.35
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -1.38 | -0.19 | +1.19 | +86.23% |
| Aug 13, 2024 | Jun 1, 2024 | -1.99 | -1.83 | +0.16 | +8.04% |
| May 14, 2024 | Mar 1, 2024 | -2.40 | -3.12 | -0.72 | -30.00% |
| Apr 1, 2024 | Dec 1, 2023 | -8.15 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | -7.20 | -6.40 | +0.80 | +11.11% |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 24, 2024 | Leerink Partners | init | — | Outperform |
| Feb 20, 2024 | Roth MKM | reit | Buy | Buy |
About Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tenaxthera.com
News
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX
- TENX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Tenax Therapeutics (TENX) Investors of Securities Class Action Lawsuit Deadline on December 28, 2026
- TENX Class Action Reminder - Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Tenax Therapeutics, Inc. Class Action Lawsuit
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Tenax Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TENX
- SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Tenax Therapeutics, Inc. (NASDAQ: TENX) -- Investors Who Suffered Losses Are Encouraged to Contact the Firm.
- Lost Money on Tenax Therapeutics, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 89.77% Share Price Drop
- ATTENTION NASDAQ: TENX INVESTORS: Contact Berger Montague About a Tenax Therapeutics, Inc. Class Action Lawsuit
- Did You Lose Money on Tenax Therapeutics, Inc. Stock? The Law Offices of Howard G.
- Kaplan Fox Encourages Tenax Therapeutics, Inc. (TENX) Investors with Significant Losses to Contact the Firm Before December 28, 2026
- TENX INVESTOR DEADLINE: Tenax Therapeutics, Inc. Investors with Substantial Losses May Seek to Lead Class Action Lawsuit
Your note
Sign in to keep a note on TENX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DAVIDSON MICHAEL H | Director | Purchase | Aug 7, 2024 | 2,881 |
| PROEHL GERALD T | Director | Purchase | Aug 7, 2024 | 1,667 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 9.96% | 339,549 | 1.86M | Sep 29, 2024 |
| Vivo Capital, LLC | 6.11% | 208,333 | 1.14M | Sep 29, 2024 |
| VR Adviser, LLC | 6.11% | 208,333 | 1.14M | Sep 29, 2024 |
| Velan Capital Investment Management LP | 2.44% | 83,333 | 457.50K | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 2.44% | 83,333 | 457.50K | Sep 29, 2024 |
| Vestal Point Capital, LP | 2.44% | 83,333 | 457.50K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Price (T.Rowe) Health Sciences Fund | 0.78% | 26,472 | 145.33K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.30% | 10,217 | 56.09K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.18% | 5,984 | 32.85K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.14% | 4,708 | 25.85K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.07% | 2,326 | 12.77K | Sep 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 364 | 2.00K | Oct 30, 2024 |